Stocktoria
Akso Health Group AHG
Nasdaq · stock · Services-Business Services, NEC · website · IPO 2017-11-03
Akso Health Group financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.8M | $14.8M | $2.4M | $13.2M | $6.3M | $1.8M | $7.0M | $82.6M | $123.3M | $29.6M |
| Gross profit | -$11,315 | -$281,526 | $122,132 | $1.3M | $605,134 | $1.8M | $6.9M | — | $107.3M | $22.9M |
| R&D expense | — | — | — | — | $421,186 | $441,405 | $117,942 | $0 | $2.8M | $1.6M |
| SG&A expense | $4.0M | $3.6M | $8.6M | — | — | — | — | — | — | — |
| Operating income | -$20.7M | -$166.3M | -$8.6M | -$14.3M | -$3.3M | -$4.2M | -$48.1M | -$7.2M | $75.9M | $9.9M |
| Interest expense | — | — | — | — | $804,138 | $2.2M | — | — | — | — |
| Income tax | -$2.0M | -$30.8M | $24,988 | $17,549 | $92,816 | $482,976 | $489,955 | $807,710 | $11.0M | $1.5M |
| Net income | -$18.7M | -$135.0M | -$9.5M | -$1.4M | -$16.9M | -$34.8M | -$71.2M | $5.5M | $65.5M | $8.6M |
| EPS (diluted) | $0.01 | $0.16 | $0.07 | $-0.02 | $-0.28 | $-0.71 | $-1.46 | $0.10 | $1.37 | $0.20 |
| Operating cash flow | -$12.8M | $1.2M | $1.4M | -$6.0M | -$11.3M | $10.1M | -$58.3M | -$1.7M | $87.7M | $8.2M |
| Free cash flow | -$12.8M | $1.0M | — | — | — | — | — | — | — | — |
| Cash & equivalents | $170,572 | $176.2M | $85.2M | $7.9M | $18.4M | $15.1M | $6.7M | $57.4M | $132.6M | $19.2M |
| Inventory | $200,135 | $190,242 | $191,201 | $1.7M | $7.8M | — | — | — | — | — |
| Total assets | $189.6M | $215.0M | $142.0M | $20.5M | $62.8M | $31.7M | $80.5M | $173.3M | $163.9M | $28.4M |
| Total liabilities | $8.7M | $15.8M | $3.6M | $11.6M | $50.5M | $14.4M | $32.4M | $46.8M | $23.8M | $4.9M |
| Shareholders' equity | $180.9M | $199.2M | $138.4M | $8.8M | $12.3M | $17.3M | $48.1M | $126.5M | $140.2M | $23.5M |
Growth · year-over-year · Revenue CAGR -8.1%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.4% | +512.1% | -81.7% | +108.9% | +256.1% | -74.5% | -91.6% | -33.0% | +316.7% | — |
| Net income growth | — | — | — | — | — | — | -1386.9% | -91.6% | +664.0% | — |
| EPS growth | -93.8% | +128.6% | — | — | — | — | -1560.0% | -92.7% | +585.0% | — |
| Free cash flow growth | -1350.9% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.